Ayman Samman Tahhan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11832766/publications.pdf

Version: 2024-02-01

331670 345221 1,359 38 21 36 g-index citations h-index papers 38 38 38 2309 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Soluble Urokinase Receptor and Acute Kidney Injury. New England Journal of Medicine, 2020, 382, 416-426.	27.0	149
2	Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials. JAMA Cardiology, 2018, 3, 1011.	6.1	146
3	Association between oxidative stress and atrial fibrillation. Heart Rhythm, 2017, 14, 1849-1855.	0.7	90
4	Enrollment of Older Patients, Women, and Racial/Ethnic Minority Groups in Contemporary Acute Coronary Syndrome Clinical Trials. JAMA Cardiology, 2020, 5, 714.	6.1	76
5	Trends in prevalence of comorbidities in heart failure clinical trials. European Journal of Heart Failure, 2020, 22, 1032-1042.	7.1	68
6	Hemodynamic, catecholamine, vasomotor and vascular responses: Determinants of myocardial ischemia during mental stress. International Journal of Cardiology, 2017, 243, 47-53.	1.7	64
7	Marital status and outcomes in patients with cardiovascular disease. Trends in Cardiovascular Medicine, 2020, 30, 215-220.	4.9	64
8	Highâ€Sensitivity Troponin I Levels and Coronary Artery Disease Severity, Progression, and Longâ€Term Outcomes. Journal of the American Heart Association, 2018, 7, .	3.7	57
9	Living in Food Deserts and Adverse Cardiovascular Outcomes in Patients With Cardiovascular Disease. Journal of the American Heart Association, 2019, 8, e010694.	3.7	57
10	Representation of Women Authors in International Heart Failure Guidelines and Contemporary Clinical Trials. Circulation: Heart Failure, 2020, 13, e006605.	3.9	55
11	Marital Status and Outcomes in Patients With Cardiovascular Disease. Journal of the American Heart Association, 2017, 6, .	3.7	54
12	Inflammatory response to mental stress and mental stress induced myocardial ischemia. Brain, Behavior, and Immunity, 2018, 68, 90-97.	4.1	41
13	Progenitor Cells and Clinical Outcomes in Patients With Heart Failure. Circulation: Heart Failure, 2017, 10, .	3.9	40
14	Progenitor Cells and Clinical Outcomes in Patients With Acute Coronary Syndromes. Circulation Research, 2018, 122, 1565-1575.	4.5	35
15	Coronary and Peripheral Vasomotor Responses to Mental Stress. Journal of the American Heart Association, 2018, 7, .	3.7	33
16	Sex Differences in Circulating Progenitor Cells. Journal of the American Heart Association, 2017, 6, .	3.7	31
17	Representativeness of a HeartÂFailure Trial by Race and Sex. JACC: Heart Failure, 2019, 7, 980-992.	4.1	30
18	Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes. Atherosclerosis, 2017, 264, 108-114.	0.8	27

#	Article	IF	CITATIONS
19	Trends in characteristics of cardiovascular clinical trials 2001-2012. American Heart Journal, 2015, 170, 263-272.e2.	2.7	26
20	Cohort profile: the Emory Cardiovascular Biobank (EmCAB). BMJ Open, 2017, 7, e018753.	1.9	26
21	Trends in Heart Failure Clinical Trials From 2001–2012. Journal of Cardiac Failure, 2016, 22, 171-179.	1.7	22
22	Differential Associations of Diastolic and Systolic Pressures With Cerebral Measures in Older Individuals With Mild Cognitive Impairment. American Journal of Hypertension, 2018, 31, 1268-1277.	2.0	21
23	Circulating Progenitor Cells and Racial Differences. Circulation Research, 2018, 123, 467-476.	4.5	18
24	Globalization of heart failure clinical trials: a systematic review of 305 trials conducted over 16 years. European Journal of Heart Failure, 2018, 20, 1068-1071.	7.1	17
25	Use of High-Sensitivity Cardiac Troponin for the Exclusion of Inducible Myocardial Ischemia. Annals of Internal Medicine, 2018, 169, 751.	3.9	16
26	Sleep Duration and Mortality in Patients With Coronary Artery Disease. American Journal of Cardiology, 2019, 123, 874-881.	1.6	16
27	Soluble Urokinaseâ€Type Plasminogen Activator Receptor and Highâ€Sensitivity Troponin Levels Predict Outcomes in Nonobstructive Coronary Artery Disease. Journal of the American Heart Association, 2020, 9, e015515.	3.7	15
28	Do Women and Men Respond Similarly toÂTherapies in Contemporary HeartÂFailure Clinical Trials?. JACC: Heart Failure, 2019, 7, 267-271.	4.1	13
29	Comparison of the Association Between High-Sensitivity Troponin I and Adverse Cardiovascular Outcomes in Patients With Versus Without Chronic Kidney Disease. American Journal of Cardiology, 2018, 121, 1461-1466.	1.6	11
30	Design Elements and Enrollment Patterns of Contemporary Trials in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2018, 6, 714-717.	4.1	8
31	Myocardial Ischemia and Mobilization of Circulating Progenitor Cells. Journal of the American Heart Association, 2018, 7, e007504.	3.7	7
32	Association Between ApoA-I (Apolipoprotein A-I) Immune Complexes and Adverse Cardiovascular Events—Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 1884-1892.	2.4	7
33	Evolving Landscape of Clinical Trials in Heart Failure: Patient Populations, Endpoint Selection, and Regions of Enrollment. Current Heart Failure Reports, 2018, 15, 10-16.	3.3	6
34	Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials. ESC Heart Failure, 2021, 8, 26-36.	3.1	6
35	Mechanisms underlying the J-curve for diastolic blood pressure: Subclinical myocardial injury and immune activation. International Journal of Cardiology, 2019, 276, 255-260.	1.7	5
36	High-Sensitivity Troponin and CoronaryÂArtery Disease Severity. JACC: Cardiovascular Imaging, 2019, 12, 1056-1057.	5. 3	1

#	Article	IF	CITATIONS
37	Trends in prevalence of comorbidities in heart failure clinical trials. , 2020, 22, 1032.		1
38	Interleukin Antagonists. Circulation: Cardiovascular Imaging, 2017, 10, .	2.6	0